Multicenter evaluation of the Selux Next-Generation Phenotyping antimicrobial susceptibility testing system.
Kristin R BakerKelly FlentieBenjamin R SpearsSergey MozharovKristen RobertsAsmae El GanbourMark SomersJohn CalkwoodJamie LiuKayla DaPonteNikitha SamGurleen KaurFelicia ChenJonathan DonatoAlan ChaoAutumn LewisJingzi ShermanKaren MortimerAmanda T HarringtonMaria TraczewskiDarcie CarpenterDee ShortridgeJill LindleyAlexander DiepEmmet NortonMatt GreenJoe GajewskiRebecca LandrithFatuma NalubegaJustin McCallumMelissa BeiswengerBrittany DolanKathleen BrennanAfton CarpenterAleksandar VacicAlec N FlyerVirginia M PierceDavid C HooperJames S Lewis IiEric SternPublished in: Journal of clinical microbiology (2023)
The Selux Next-Generation Phenotyping (NGP) system (Charlestown, MA) is a new antimicrobial susceptibility testing system that utilizes two sequential assays performed on all wells of doubling dilution series to determine MICs. A multicenter evaluation of the performance of the Selux NGP system compared with reference broth microdilution was conducted following FDA recommendations and using FDA-defined breakpoints. A total of 2,488 clinical and challenge isolates were included; gram-negative isolates were tested against 24 antimicrobials, and gram-positive isolates were tested against 15 antimicrobials. Data is provided for all organism-antimicrobial combinations evaluated, including those that did and did not meet FDA performance requirements. Overall very major error and major error rates were less than 1% (31/3,805 and 107/15,606, respectively), essential agreement and categorical agreement were >95%, reproducibility was ≥95%, and the average time-to-result (from time of assay start to time of MIC result) was 5.65 hours.